Researchers developed a new computational approach to predict chemotherapy response in triple-negative breast cancer, outperforming current methods. The TmS biomarker accurately sorts patients into those with favorable or poor prognosis, highlighting its potential as an effective starting point for patient stratification.
The Phase I/II multicenter international CADENZA trial found that 75% of patients with BPDCN treated with pivekimab sunirine achieved a complete response. The treatment delivered the therapeutic drug directly to cancer cells, resulting in rapid cancer cell death with limited targeting of healthy tissue.
Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.
A study found that 60.8% of American women prefer in-clinic cervical cancer screening, while 20.4% opt for at-home self-sampling. Marginalized groups, including those with low income and distrust of healthcare systems, are more likely to choose at-home options.
The Journey to End Cancer exhibition guides visitors through the full spectrum of cancer science from cause to cure. Featuring interactive experiences, immersive media environments, and inspiring first-person videos, the exhibit aims to educate and empower visitors about cancer prevention and treatment.
A meta-analysis of individual patients with oligometastatic prostate cancer shows that metastasis-directed radiation therapy (MDT) significantly improves patient outcomes, including delayed disease progression and better quality of life. The study included 574 men and found a median of 7.6 months before disease progression in the MDT a...
Iakovos Toumazis leads IDSO's focus area on decision analytics for health to optimize patient outcomes and resource allocation. His research informs data-driven approaches to cancer prevention and policy decisions.
Researchers identified a targetable driver of brain metastases in inflammatory breast cancer, promoting tumor invasion and triggering brain inflammation via the CXCR2 signaling pathway. Targeting sEcad or the CXCR2 pathway may treat or prevent brain metastasis.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Researchers found that combining selective CDK2 inhibitor BLU-222 with CDK4/6 inhibitors produces strong, durable anti-tumor effects across preclinical models of breast cancer. This approach targets cancer cells' reliance on CDK proteins and restores control over the cell cycle in resistant tumors.
Researchers developed engineered bispecific nanobodies that bind viruses to mucus, preventing infection. The approach was effective in preclinical models of multiple respiratory viruses, offering immediate, localized protection.
Researchers found that NOUS-209 safely stimulated the immune system to target precancerous and cancerous cells in individuals with Lynch Syndrome, providing early evidence of its potential to intercept cancer before it develops. The vaccine-induced T cells were able to kill tumor cells and showed signs of long-lasting immune memory.
A Phase I study led by Timothy Yap demonstrates the potential of linavonkibart to target and prevent activation of transforming growth factor-beta 1 (TGFβ1), overcoming treatment resistance in multiple cancers. The trial showed manageable safety profiles and objective responses in heavily pre-treated patients, suggesting a promising ne...
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
Researchers discovered that high levels of protein BATF2 drive tumor immune suppression in head and neck cancer. Glutamine in the tumor microenvironment silences BATF2, affecting the STING signaling pathway and overall immune response.
A study published in PNAS reveals that peripheral neuropathy can reduce macrophage immune cells' ability to clear dead cells through efferocytosis, leading to chronic pain. Restoring this process may offer a new therapeutic strategy to prevent inflammatory signaling and improve nerve repair.
The collaboration aims to integrate AI-powered analytics with clinical expertise to accelerate data-driven cancer care. MD Anderson researchers will leverage SOPHIAs AI technologies to develop bioinformatics pipelines for rapid RNA-sequencing data interpretation.
Researchers have identified Rb1 as a predictive biomarker for a new therapeutic strategy in some breast cancers. The study found that simultaneous inhibition of ATR and PKMYT1 triggers cell death in Rb1-deficient breast cancer models, leading to tumor shrinkage and improved survival.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
A Phase III trial has demonstrated the survival benefit of proton therapy compared to traditional radiation therapy for oropharyngeal cancer patients, with improved overall survival at five years. Proton therapy also resulted in reduced toxicities and feeding tube dependence, highlighting its potential as a standard treatment option.
Researchers present promising new data from two ongoing studies of pivekimab sunirine targeting CD123 in treating two aggressive blood cancers, acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The triplet regimen including pivekimab sunirine showed high response rates and enabled stem cell transpla...
A new study by University of Texas M.D. Anderson Cancer Center researchers identified CD40 overexpression as a potential biomarker associated with improved overall survival in angioimmunoblastic T cell lymphoma (AITL). This discovery could lead to therapeutic strategies to improve outcomes for this challenging disease.
Patients with lower-risk myelodysplastic syndromes experienced strong responses with fewer side effects when treated with a five-day azacitidine compared to shorter durations. The five-day regimen offered the best balance of safety and efficacy, demonstrating improved event-free survival and overall survival.
The TRANSCEND FL trial demonstrates the effectiveness of lisocabtagene maraleucel in achieving durable remissions and favorable safety profiles in patients with relapsed or refractory follicular lymphoma. The therapy produced a 97% overall response rate, with most patients remaining in remission after three years.
The Phase II trial of anito-cel demonstrated a high overall response rate of 97% and complete response rate of 68% in patients with refractory multiple myeloma. The therapy also showed a favorable safety profile, with manageable side effects.
Researchers developed an antibody therapy called 77A that targets HSP70, a heat shock protein helping tumors evade the immune system. The treatment showed strong antitumor effects by enhancing immune cell activity in laboratory models of multiple cancer types.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
A specific protein, RASH3D19, activates the RAS signaling pathway involved in aggressive tumor growth and resistance to KRAS inhibitors. Blocking RASH3D19 improves outcomes in preclinical models, suggesting a potential therapeutic strategy.
A study compares five DNA foundation language models across 57 diverse datasets to identify their strengths and weaknesses in predicting gene expression, identifying genomic components, and detecting harmful mutations. The findings highlight the importance of selecting appropriate models based on specific genomic tasks.
A new study by University of Texas M. D. Anderson Cancer Center researchers has identified a myeloid mimicry pathway that drives tumor hyper progression following immunotherapy in renal medullary carcinoma, highlighting specific targets for overcoming treatment resistance.
Zanidatamab demonstrated significant efficacy in patients with HER2-positive biliary tract cancer, achieving response rates of up to 51.6% and improving symptoms such as pain levels. The trial's results support the emerging role of zanidatamab as a treatment paradigm for this rare and aggressive cancer.
Researchers at the University of Texas M. D. Anderson Cancer Center discovered that inflexible DNA within nucleosomes regulates the positioning of INO80, a chromatin remodeling complex. This unique mechanism allows INO80 to position itself on the surface of nucleosomes at the right location.
Researchers at MD Anderson have discovered bacterial genetic and cellular elements within brain tumor cells, potentially influencing tumor behavior. Inflammation may also drive the earliest stages of lung cancer, with targeting proinflammatory pathways emerging as a potential early intervention approach
Researchers have discovered a new class of BRCA1 mutations that can be targeted by HSP90 inhibitors, potentially improving treatment outcomes for patients with breast cancer. The study found that these mutations are more resistant to PARP inhibitor treatment but can be overcome with low-dose HSP90 inhibition.
The University of Texas MD Anderson Cancer Center has been awarded $29 million by the Cancer Prevention and Research Institute of Texas (CPRIT) to support impactful prevention programs and groundbreaking cancer research. The funding will also enable the recruitment of a CPRIT Scholar.
A study published in Nature Medicine found bacterial genetic and cellular elements inside brain tumor cells, potentially influencing tumor progression and treatment outcomes. The researchers also linked these bacterial elements to specific immune and metabolic responses in brain tumors.
The University of Texas MD Anderson Cancer Center has launched a historic $2.5 billion philanthropic campaign to end cancer, with an initial $1.9 billion raised. The campaign focuses on expanding reach, expediting breakthroughs, and elevating the patient experience.
Researchers at MD Anderson Cancer Center are sharing new insights on training the immune system to improve patient outcomes. Key findings include the potential of gut microbiome manipulation in improving immunotherapy responses and developing novel treatments for patients with EGFR-positive lung cancer.
Researchers at University of Texas M. D. Anderson Cancer Center discover that inflammation is responsible for driving the earliest stages of lung cancer, identifying potential targets for early intervention and suggesting a promising approach to intercepting lung cancer development.
A comprehensive molecular analysis of renal medullary carcinoma identified overexpression of TROP2 and the Hippo pathway in patients. The study found sacituzumab govitecan to result in partial responses and stable disease in heavily pretreated RMC patients.
Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...
A new study found that more than half of American adults misunderstand the link between alcohol consumption and cancer. Alcohol drinkers are particularly likely to believe drinking has no effect on cancer risk. Correcting these misbeliefs may strengthen adherence to U.S. Surgeon General’s guidelines for lowering cancer risk.
The Allison Institute's third annual scientific symposium featured a panel discussion with five Nobel laureates, highlighting breakthroughs in cancer vaccines, immunotherapy, and immunology research. The event also recognized scientific achievement and leadership through award presentations.
The University of Texas MD Anderson Cancer Center has honored two outstanding nurses, Kimberly Vanderhorst and Terri Lynn Dunn, with the 2025 Brown Foundation Award for Excellence in Oncology Nursing. The award recognizes exceptional patient care and a commitment to excellence in clinical practice.
A study by University of Texas MD Anderson Cancer Center researchers has identified seven distinct cellular microenvironments in diffuse large B-cell lymphoma (DLBCL) tumors. These microenvironments showed different mixes of cells and patterns of communication between tumor B-cells and immune cells.
Patients receiving mRNA-based COVID vaccines showed improved survival rates and responses to immunotherapy, especially in 'cold' tumors with low PD-L1 expression. The study suggests that these vaccines can reprogram immune responses against cancer, potentially improving outcomes for patients with treatment-resistant disease.
The VT3989 trial demonstrated a disease control rate of 86% in refractory mesothelioma patients, with notable partial responses and stable disease. The YAP-TEAD inhibitor also showed an encouraging safety profile, supporting continued clinical development in this unmet clinical need.
A Phase II clinical trial led by researchers at the University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma. Belzutifan showed a 26% objective response rate, with sustained clinical benefits for those who responded to treatment.
A randomized trial found that patients with metastatic clear-cell renal carcinoma lived longer without disease progression when treated with lenvatinib and everolimus compared to cabozantinib. The study suggests that lenvatinib plus everolimus may offer a more meaningful benefit as second-line treatment for these patients.